About AskBio
AskBio is a company based in Durham (United States) founded in 2001 by Jude Samulski and Sheila Mikhail was acquired by Bayer in October 2020. AskBio has raised $235 million across 8 funding rounds from investors including Bayer, TPG and HHS. AskBio has completed 2 acquisitions, including Brain Vectis and Synpromics. AskBio offers products and services including AAV Gene Therapy Platform and Discovery Program. AskBio operates in a competitive market with competitors including Jazz Pharmaceuticals, Spark Therapeutics, Amyris, Biogen and Neurocrine, among others.
- Headquarter Durham, United States
- Founders Jude Samulski, Sheila Mikhail
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Synpromics Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$235 M (USD)
in 8 rounds
-
Latest Funding Round
$2.68 M (USD), Grant
Sep 02, 2020
-
Investors
Bayer
& 4 more
-
Employee Count
Not available
-
Investments & Acquisitions
Brain Vectis
& 1 more
-
Acquired by
Bayer
(Oct 26, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AskBio
AskBio offers a comprehensive portfolio of products and services, including AAV Gene Therapy Platform and Discovery Program.
Platform for developing treatments targeting genetic diseases using AAV vectors.
Program enabling partnerships for advancing gene therapy innovations.
People of AskBio
Unlock access to complete
Leadership Team
37 people
Software Development Team
21 people
Product Management Team
14 people
Scientist Team
12 people
Senior Team
8 people
Operations Team
7 people
Research Team
5 people
Human Resources and Administration
3 people
Unlock access to complete
Funding Insights of AskBio
AskBio has successfully raised a total of $235M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $2.68 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AskBio
AskBio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Bayer, TPG and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Locked | Locked | Locked | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Business development and leadership training programs are offered to companies.
|
Locked | Locked | Locked |
Investor details for AskBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AskBio
AskBio has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Brain Vectis and Synpromics.
Investment portfolio details for AskBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease
|
Locked | Locked | 2015 | Locked | |
|
Synthetic promoters are designed for specific gene regulation.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for AskBio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - AskBio
Detailed financials for AskBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Askbio Comparisons
Peer comparison for AskBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AskBio
AskBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Spark Therapeutics, Amyris, Biogen and Neurocrine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of AskBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Askbio
Complete news archive for AskBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AskBio
AskBio was founded in 2001 and raised its 1st funding round 7 years after it was founded.
AskBio is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Sheila Mikhail is the current CEO of AskBio. They have also founded this company.
AskBio is a funded company, having raised a total of $235M across 8 funding rounds to date.
AskBio was founded in 2001 in Durham, United States, and operates in the biotechnology sector. Novel protein and cellular-based therapies are developed and delivered using a proprietary platform of recombinant adeno-associated virus biological nanoparticles. This technology enables high transduction efficiency, controlled expression, and targeted tissue delivery. The product pipeline encompasses treatments for muscular dystrophy, hemophilia B in Phase 1 trials, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.
AskBio's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and Syngenta.
AskBio offers AAV Gene Therapy Platform and Discovery Program.
AskBio has made 2 acquisitions, including Brain Vectis, and Synpromics.
AskBio has 5 investors. Key investors include Bayer, TPG, HHS, Scottish Enterprise, and Vida Ventures.